KR102397961B1 - 유전자 변형된 ｔ 세포 수용체 마우스 - Google Patents

유전자 변형된 ｔ 세포 수용체 마우스 Download PDF

Info

Publication number
KR102397961B1
KR102397961B1 KR1020217035333A KR20217035333A KR102397961B1 KR 102397961 B1 KR102397961 B1 KR 102397961B1 KR 1020217035333 A KR1020217035333 A KR 1020217035333A KR 20217035333 A KR20217035333 A KR 20217035333A KR 102397961 B1 KR102397961 B1 KR 102397961B1
Authority
KR
South Korea
Prior art keywords
human
tcr
gene segments
gene
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217035333A
Other languages
English (en)
Korean (ko)
Other versions
KR20210133325A (ko
Inventor
린 맥도날드
앤드류 제이. 머피
존 맥훠터
나신 투
베라 보로니나
카간 규레르
캐롤리나 미거
션 스티븐스
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020227015694A priority Critical patent/KR102542272B1/ko
Publication of KR20210133325A publication Critical patent/KR20210133325A/ko
Application granted granted Critical
Publication of KR102397961B1 publication Critical patent/KR102397961B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020217035333A 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스 Active KR102397961B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227015694A KR102542272B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161552582P 2011-10-28 2011-10-28
US61/552,582 2011-10-28
US201261621198P 2012-04-06 2012-04-06
US61/621,198 2012-04-06
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
PCT/US2012/062065 WO2013063361A1 (en) 2011-10-28 2012-10-26 Genetically modified t cell receptor mice
KR1020207024033A KR102321909B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024033A Division KR102321909B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015694A Division KR102542272B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스

Publications (2)

Publication Number Publication Date
KR20210133325A KR20210133325A (ko) 2021-11-05
KR102397961B1 true KR102397961B1 (ko) 2022-05-13

Family

ID=47178340

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217035333A Active KR102397961B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020227015694A Active KR102542272B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020197008815A Active KR102148387B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020147014477A Active KR101964776B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020207024033A Active KR102321909B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020227015694A Active KR102542272B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020197008815A Active KR102148387B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020147014477A Active KR101964776B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스
KR1020207024033A Active KR102321909B1 (ko) 2011-10-28 2012-10-26 유전자 변형된 ｔ 세포 수용체 마우스

Country Status (25)

Country Link
US (4) US9113616B2 (enExample)
EP (3) EP3424947B1 (enExample)
JP (7) JP6254528B2 (enExample)
KR (5) KR102397961B1 (enExample)
CN (5) CN114891798B (enExample)
AU (5) AU2012327204B2 (enExample)
BR (1) BR112014009203B1 (enExample)
CA (1) CA2853707A1 (enExample)
CY (2) CY1120945T1 (enExample)
DK (2) DK3424947T3 (enExample)
ES (2) ES2691475T3 (enExample)
HR (2) HRP20181626T1 (enExample)
HU (1) HUE053444T2 (enExample)
IL (4) IL305550B2 (enExample)
IN (1) IN2014CN03890A (enExample)
LT (2) LT3424947T (enExample)
MX (2) MX353134B (enExample)
PL (2) PL3424947T3 (enExample)
PT (2) PT2771357T (enExample)
RS (2) RS57893B1 (enExample)
RU (1) RU2661106C2 (enExample)
SG (2) SG11201401030WA (enExample)
SI (2) SI3424947T1 (enExample)
SM (2) SMT201800553T1 (enExample)
WO (1) WO2013063361A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053444T2 (hu) * 2011-10-28 2021-06-28 Regeneron Pharma Genetikailag módosított T-sejt receptoros egerek
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2645475C2 (ru) 2012-04-25 2018-02-21 Регенерон Фармасьютикалз, Инк. Опосредованное нуклеазой нацеливание с большими нацеливающими векторами
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
EP3683238A1 (en) * 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
PT3161128T (pt) 2014-06-26 2018-11-21 Regeneron Pharma Métodos e composições para modificações genéticas alvejadas e métodos de utilização
KR20170083534A (ko) * 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
CA2968440A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
KR102659123B1 (ko) * 2014-11-24 2024-04-22 리제너론 파마슈티칼스 인코포레이티드 인간화 cd3 복합체를 발현하는 비인간 동물
BR112017013104A2 (en) 2014-12-19 2018-05-15 Regeneron Pharmaceuticals, Inc. methods for modifying a target genomic locus in a cell, for enhancing homologous recombination at a target genomic locus in a cell, and for producing an f0 generation from a nonhuman animal.
RU2732628C2 (ru) * 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
KR20200091499A (ko) 2015-05-06 2020-07-30 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
KR102454546B1 (ko) * 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
CA3020330A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
MA44608B1 (fr) 2016-04-08 2022-06-30 Immunocore Ltd Récepteurs des lymphocytes t
KR102483193B1 (ko) * 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
AU2018283319B2 (en) 2017-06-16 2023-11-09 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3775238A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
AU2019312008B2 (en) * 2018-07-26 2026-04-23 Kyoto University Method for generating cells into which an exogenous antigen receptor is introduced
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
AU2020344628A1 (en) * 2019-09-12 2022-04-07 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
WO2021195503A1 (en) * 2020-03-27 2021-09-30 2Seventy Bio, Inc. T cell receptors
CN113684258B (zh) 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
US12376573B2 (en) 2021-03-31 2025-08-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN120019068A (zh) * 2022-08-12 2025-05-16 独创目标实验室 具有人源化γ和δTCR可变基因的经遗传修饰的非人类
JP2025527575A (ja) 2022-08-18 2025-08-22 イミュノコア リミテッド Ｍａｇｅ ａ４に特異的なｔ細胞受容体融合タンパク質
US20240099279A1 (en) * 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
GB2640828A (en) 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs
GB2642411A (en) 2024-04-22 2026-01-14 T Therapeutics Ltd T Cell Receptor identification and provision

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006639A1 (fr) 2001-07-13 2003-01-23 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2005004592A2 (en) 2003-07-30 2005-01-20 Institut Pasteur Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
JP2005505236A (ja) 2000-12-19 2005-02-24 アルトー バイオサイエンス コーポレイション ヒト化免疫系を含むトランスジェニック動物
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
WO2008010100A2 (en) 2006-07-13 2008-01-24 Institut Pasteur Immunodeficient mice transgenic for hla class i and hla class ii molecules and their uses
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
AU728794B2 (en) 1996-03-05 2001-01-18 Scripps Research Institute, The Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens
US6320306B1 (en) * 1996-08-05 2001-11-20 Samsung Display Devices Co., Ltd. Shadow mask with porous insulating layer and heavy metal layer
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
WO2003041495A1 (en) 2001-11-15 2003-05-22 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
DK1321477T3 (da) 2001-12-22 2005-02-14 4Antibody Ag Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
WO2004042004A2 (en) 2002-10-30 2004-05-21 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
US9388425B2 (en) 2006-10-20 2016-07-12 Trustees Of Boston University Tunable genetic switch for regulating gene expression
JP2008159109A (ja) 2006-12-21 2008-07-10 Matsushita Electric Ind Co Ltd データ転送装置
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) * 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US9557323B2 (en) 2010-09-24 2017-01-31 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CN105950654B (zh) 2010-11-27 2020-03-20 朱坚 一种人源化的转基因动物
HUE053444T2 (hu) * 2011-10-28 2021-06-28 Regeneron Pharma Genetikailag módosított T-sejt receptoros egerek
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
JP2005505236A (ja) 2000-12-19 2005-02-24 アルトー バイオサイエンス コーポレイション ヒト化免疫系を含むトランスジェニック動物
WO2003006639A1 (fr) 2001-07-13 2003-01-23 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2005004592A2 (en) 2003-07-30 2005-01-20 Institut Pasteur Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
WO2008010100A2 (en) 2006-07-13 2008-01-24 Institut Pasteur Immunodeficient mice transgenic for hla class i and hla class ii molecules and their uses
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Eur. J. Immunol., vol.19(12), pp.2349-2354(1989).
J. Exp. Med., vol.170(4), pp.1091-1101(1989).
J. Exp. Med., vol.173(4), pp.1007-1015(1991).
J. Immunol., vol.149(1), pp.136-142(1992).
Nature, vol. 348(6302), pp.642-644(1990.12.13).

Also Published As

Publication number Publication date
JP2014532413A (ja) 2014-12-08
KR102148387B1 (ko) 2020-08-26
KR102542272B1 (ko) 2023-06-13
US20220386575A1 (en) 2022-12-08
HRP20181626T1 (hr) 2018-12-14
AU2018204700A1 (en) 2018-07-19
RU2014121160A (ru) 2015-12-10
AU2012327204A1 (en) 2013-05-23
IN2014CN03890A (enExample) 2015-10-16
JP7305840B2 (ja) 2023-07-10
JP2020146045A (ja) 2020-09-17
JP6254528B2 (ja) 2017-12-27
IL274914B2 (en) 2024-02-01
MX379517B (es) 2025-03-10
AU2021203192B2 (en) 2024-04-11
AU2016202512A1 (en) 2016-05-12
CN107858333A (zh) 2018-03-30
CA2853707A1 (en) 2013-05-02
JP2018007696A (ja) 2018-01-18
IL305550B2 (en) 2025-02-01
CN107858333B (zh) 2022-05-27
LT2771357T (lt) 2018-10-25
SI2771357T1 (sl) 2018-11-30
RS61455B1 (sr) 2021-03-31
SG11201401030WA (en) 2014-04-28
US20130109053A1 (en) 2013-05-02
PL3424947T3 (pl) 2021-06-14
IL315445A (en) 2024-11-01
CY1120945T1 (el) 2019-12-11
US9113616B2 (en) 2015-08-25
JP2019033770A (ja) 2019-03-07
IL274914A (en) 2020-07-30
IL274914B1 (en) 2023-10-01
BR112014009203A2 (pt) 2020-10-27
JP2023024744A (ja) 2023-02-16
EP2771357B1 (en) 2018-07-18
AU2024204645A1 (en) 2024-08-01
CN114891797A (zh) 2022-08-12
KR20190037354A (ko) 2019-04-05
KR101964776B1 (ko) 2019-04-04
MX2014004894A (es) 2014-09-12
EP3424947B1 (en) 2020-11-25
US20210051930A1 (en) 2021-02-25
US11528895B2 (en) 2022-12-20
ES2691475T3 (es) 2018-11-27
CY1123831T1 (el) 2022-05-27
HUE053444T2 (hu) 2021-06-28
SI3424947T1 (sl) 2021-04-30
NZ623147A (en) 2016-03-31
AU2012327204B2 (en) 2016-01-21
HK1198171A1 (en) 2015-03-13
CN114891798A (zh) 2022-08-12
SG10201914043XA (en) 2020-03-30
US12582105B2 (en) 2026-03-24
EP3795587A1 (en) 2021-03-24
EP3424947A1 (en) 2019-01-09
EP2771357A1 (en) 2014-09-03
PL2771357T3 (pl) 2018-12-31
US20160021856A1 (en) 2016-01-28
CN107858332A (zh) 2018-03-30
WO2013063361A1 (en) 2013-05-02
SMT201800553T1 (it) 2018-11-09
IL305550A (en) 2023-10-01
DK2771357T3 (en) 2018-10-29
AU2018204700B2 (en) 2021-04-01
KR20140077219A (ko) 2014-06-23
IL232098B (en) 2020-06-30
JP2024019646A (ja) 2024-02-09
AU2021203192A1 (en) 2021-06-10
JP7656580B2 (ja) 2025-04-03
PT3424947T (pt) 2021-03-01
AU2018204700C1 (en) 2021-10-14
KR20200102001A (ko) 2020-08-28
CN104011071A (zh) 2014-08-27
IL305550B1 (en) 2024-10-01
BR112014009203B1 (pt) 2023-02-28
PT2771357T (pt) 2018-11-09
AU2016202512C1 (en) 2018-10-11
AU2016202512B2 (en) 2018-03-29
SMT202100243T1 (it) 2021-05-07
ES2858978T3 (es) 2021-09-30
DK3424947T3 (da) 2021-02-22
IL232098A0 (en) 2014-05-28
JP6532924B2 (ja) 2019-06-19
LT3424947T (lt) 2021-03-10
CN104011071B (zh) 2017-11-07
KR20220066197A (ko) 2022-05-23
RS57893B1 (sr) 2019-01-31
HRP20210256T1 (hr) 2021-04-02
KR20210133325A (ko) 2021-11-05
RU2661106C2 (ru) 2018-07-11
MX353134B (es) 2017-12-20
CN114891798B (zh) 2025-12-02
KR102321909B1 (ko) 2021-11-05
JP2022093637A (ja) 2022-06-23
JP6706311B2 (ja) 2020-06-03

Similar Documents

Publication Publication Date Title
JP7656580B2 (ja) 遺伝子改変ｔ細胞受容体マウス
HK40049273A (en) Genetically modified t cell receptor mice
HK40002846A (en) Genetically modified t cell receptor mice
HK40002846B (en) Genetically modified t cell receptor mice
HK1198171B (en) Genetically modified t cell receptor mice

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211029

Application number text: 1020207024033

Filing date: 20200820

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211217

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220209

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220510

Application number text: 1020207024033

Filing date: 20200820

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220510

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220511

End annual number: 3

Start annual number: 1

PG1601 Publication of registration